Correction: Kim et al. Cell Surface GRP94 as a Novel Emerging Therapeutic Target for Monoclonal Antibody Cancer Therapy. Cells 2021, 10, 670

The authors wish to acknowledge that: [...]no clinical study with PU-H71 conducted by Samus Therapeutics or others has experienced life-threatening grade IV hematologic toxicities. [...]PU-H71 is currently be administered in several active Phase 1b clinical studies. [...]the sentences “PU-H71, first discovered by Memorial Sloan-Kettering Cancer Center, has undergone a phase I clinical trial by Samus Therapeutics. First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profile.